| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
0 | 0 | 0 | 0 | 0 |
| Selling, General and Administrative Expenses
|
-11,331.0340 | -8,430.8380 | -6,476.6270 | -8,171.1420 | -4,022.0210 |
|
Research and Development Expenses
|
-1,856.9110 | -828.0010 | -282.5430 | -90.2700 | 0 |
|
Operating Income/Expenses
|
-13,187.9450 | -9,258.8390 | -6,759.1700 | -8,261.4120 | -4,022.0210 |
|
Total Operating Profit/Loss
|
-13,187.9450 | -9,258.8390 | -6,759.1700 | -8,261.4120 | -4,022.0210 |
| Total Net Finance Income/Expense
|
368.9270 | 17.5920 | 6.6180 | -232.4160 | -442.9130 |
| Net Investment Income
|
638.9120 | 11.5500 | -43.9710 | 13.2070 | -171.0370 |
| Irregular Income/Expenses
|
-- | -- | -- | 0 | -1,071.0630 |
|
Other Income/Expense, Non-Operating
|
35.5300 | 86.8850 | 0 | 28.6540 | 8.5000 |
|
Non-Operating Income/Expenses, Total
|
1,043.3690 | 116.0270 | -37.3530 | -190.5550 | -1,676.5130 |
|
Pretax Income
|
-12,144.5760 | -9,142.8120 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
|
Net Income from Continuing Operations
|
-12,144.5760 | -9,142.8120 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-12,144.5760 | -9,142.8120 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
|
Net Income after Non-Controlling/Minority Interests
|
-12,144.5760 | -9,142.8110 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
|
Net Income Available to Common Stockholders
|
-12,144.5760 | -9,142.8110 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
|
Diluted Net Income Available to Common Stockholders
|
-12,144.5760 | -9,142.8110 | -6,796.5230 | -8,451.9670 | -5,698.5340 |
| Basic EPS
|
-0.07 | -0.06 | -0.05 | -0.07 | -0.06 |
| Diluted EPS
|
-0.07 | -0.06 | -0.05 | -0.07 | -0.06 |
|
Basic Weighted Average Shares Outstanding
|
182,280.0050 | 154,606.7810 | 137,089.7380 | 125,780.8610 | 93,058.1790 |
|
Diluted Weighted Average Shares Outstanding
|
182,280.0050 | 154,606.7810 | 137,089.7380 | 125,780.8610 | 93,058.1790 |
|
EBIT
|
-12,513.5030 | -9,160.4040 | -6,803.1410 | -8,219.5510 | -5,255.6210 |
|
EBITDA
|
-12,408.9170 | -9,074.3090 | -6,786.9530 | -8,202.5240 | -5,249.2470 |
|
Normalized EBITDA
|
-9,883.2710 | -5,866.2090 | -3,576.0720 | -4,516.9590 | -4,127.2570 |
|
Normalized Income
|
-9,618.9300 | -5,934.7120 | -3,585.6420 | -4,766.4020 | -4,576.5440 |
|
Total Unusual Items
|
2,525.6460 | 3,208.1000 | 3,210.8810 | 3,685.5650 | 1,121.9900 |
|
Total Unusual Items Excluding Goodwill
|
2,525.6460 | 3,208.1000 | 3,210.8810 | 3,685.5650 | 1,121.9900 |
|
Tax Effect of Unusual Items
|
0 | 0 | 0 | 0 | 0 |
|
Tax Rate, Calculated
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12/31/2022 - 12/31/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade